Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility

Phillips, Peter; Zemcov, Janet; Mahmood, Wafeeq; Montaner, Julio S.G.; Craib, Kevin; Clarke, Alison M.

doi:10.1097/00002030-199610000-00009

Cited by 88Antifungal resistance and susceptibilityHIV/AIDS oral health manifestationsFungal Infections and Studies

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility

Phillips, Peter, Zemcov, Janet, Mahmood, Wafeeq, Montaner, Julio S.G., Craib, Kevin, Clarke, Alison M.·1996·AIDS

DOI 10.1097/00002030-199610000-00009

Open this paper in CoChat — free account

Abstract

Objective To evaluate the efficacy of itraconazole cyclodextrin solution in fluconazole-refractory oropharyngeal candidiasis (OPC), and to correlate clinical outcome with in vitro susceptibility and serum azole levels. Design A prospective, open-label, intervention study. Setting A university hospital, which serves as the provincial HIV referral center. Patients and interventions Thirty six HIV-infected individuals referred for fluconazole-refractory OPC were evaluated prospectively between May 1993 and March 1995, including clinical assessment, serum azole levels, and susceptibility testing of Candida spp, isolates. Itraconazole solution was administered orally at a daily dose of 200 mg for 14 days, followed by suppressive therapy. Thirty-four patients were evaluable. Main outcome measure Resolution of oral pseudomembranous lesions. Results Initial isolates were Candida albicans (n = 33), C. glabrata (n = 1), C. krusei (n = 1), and mixed infection with C. albicans and C. krusei (n = 1). Fluconazole serum levels obtained at the time of failed therapy ranged from 4.7 to 40 mg/l (median, 12.9 mg/l). Itraconazole was generally well tolerated. Clinical responses were observed in 65% (22 out of 34) of evaluable cases. Among the responders, relapse had occurred within 2 months for four (36%) out of 11 cases who continued with follow-up. The median fluconazole minimal inhibitory concentration (MIC) was 64 mg/l for isolates from fluconazole-refractory cases, compared with a median of…

Integrity signals

Registry

Crossref · 10.1097/00002030-199610000-00009

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Between 64% and 80% of patients with fluconazole-refractory oropharyngeal candidiasis respond to itraconazole solution.
“Between 64% and 80% of patients with fluconazole-refractory infections will respond to treatment with itraconazole solution [268][269][270].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [268]

Sorted by citations

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
“Fluconazole-refractory infections should be treated initially with itraconazole solution; between 64% and 80% of patients will respond to this therapy [546, 547].”
Background
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
“Between 64% and 80% of patients will respond to this therapy [251, 262].”
Background
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
“to treatment with itraconazole solution [268–270].”
Influential
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137 · see citing works
“In two studies, patients complained about the taste of the itraconazole oral solution (98, 195), which did not appear to interfere with compliance among HIV-infected patients (195) but which was associated with nausea immediately after ingestion in patients with chemotherapy-induced neutropenia (98).”
BackgroundInfluential
<i>Candida glabrata</i> : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to <i>C. albicans</i>
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953 · see citing works
“glabrata producing OPC was less than 10% (16, 121).”
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
“Approximately 64% of patients with fluconazole-refractory infections will respond to itraconazole solution [140].”
Background
Oral candidiasis
Akpan, A., & Morgan, R. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.922.455 · Cited by 578 · see citing works
Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254 · see citing works
Oral Candidal Infections and Antimycotics
Ellepola, A. N. B., & Samaranayake, L. P. (2000) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411000110020301 · Cited by 243 · see citing works
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
MOFENSON, L. M., Brady, M. T., Danner, S. P., Dominguez, K. L., Hazra, R., Handelsman, E. L., Havens, P. L., Nesheim, S. R., Read, J. S., Serchuck, L. K., et al. (2009) · PubMed · Cited by 221 · see citing works
Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., & Jessen, L. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1862 · Cited by 207 · see citing works
Oropharyngeal candidiasis in the era of antiretroviral therapy
Thompson, G. R., Patel, P., Kirkpatrick, W. R., Westbrook, S. D., Berg, D., Erlandsen, J. E., Redding, S. W., & Patterson, T. F. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.11.026 · Cited by 164 · see citing works
Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects with HIV Infection
Skiest, D. J., Vazquez, J. A., Anstead, G. M., Graybill, J. R., Reynes, J., Ward, D., Hare, R., Boparai, N., & Isaacs, R. (2007) · Clinical Infectious Diseases · doi:10.1086/511039 · Cited by 162 · see citing works
The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review
Martin, M. V. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.4.429 · Cited by 149 · see citing works
“Among 36 HIVpositive patients who were non-responsive to fluconazole for oropharyngeal candidosis, 65% responded to itraconazole solution.(79) Itraconazole solution is recommended for the treatment of oral and oesophageal candidosis in AIDS patients who are non-responsive to fluconazole, but a”
Background
Treating Opportunistic Infections among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America
MOFENSON, L. M., Oleske, J. M., Serchuck, L. K., Dyke, R. V., & Wilfert, C. (2005) · Clinical Infectious Diseases · doi:10.1086/427295 · Cited by 135 · see citing works
Itraconazole in Cyclodextrin Solution
Stevens, D. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.8.603.31529 · Cited by 129 · see citing works
Photodynamic inactivation for controlling Candida albicans infections
Gonzales, F. P., & Maisch, T. (2011) · Fungal Biology · doi:10.1016/j.funbio.2011.10.001 · Cited by 127 · see citing works
Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis
Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2554-2563.2002 · Cited by 123 · see citing works
Antifungal Agents. Part II. The Azoles
Terrell, C. L. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.1.78 · Cited by 116 · see citing works
ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
Lortholary, O., Πετρίκκος, Γ., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12042 · Cited by 108 · see citing works
“amphotericin B formulation D III No role for the management of OEC due to azole susceptible isolates Local treatments D III Less effective than fluconazole Treatment of refractory OPC/OEC Itraconazole oral solution (‡200 mg/day) A II [64][63][65] Posaconazole (400 mg twice daily) A II [66][67] Voriconazole (200 mg twi…”
Background
Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children
Siberry, G. K., Abzug, M. J., Nachman, S., Brady, M. T., Dominguez, K. L., Handelsman, E. L., MOFENSON, L. M., & Nesheim, S. R. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000437856.09540.11 · Cited by 111 · see citing works
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children
Pienaar, E. D., Young, T., & Holmes, H. K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003940.pub3 · Cited by 104 · see citing works
Refractory Mucosal Candidiasis in Advanced Human Immunodeficiency Virus Infection
Fichtenbaum, C. J., Koletar, S. L., Yiannoutsos, C. T., Holland, F., Pottage, J. C., Cohn, S. E., Walawander, A., Frame, P. T., Feinberg, J., Saag, M. S., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313765 · Cited by 99 · see citing works
Current Management of Fungal Infections
Meis, J. F. G. M., & Verweij, P. E. (2001) · Drugs · doi:10.2165/00003495-200161001-00002 · Cited by 102 · see citing works
Emergence of Resistance to Fluconazole as a Cause of Failure during Treatment of Histoplasmosis in Patients with Acquired Immunodeficiency Disease Syndrome
Wheat, L. J., Connolly, P., Smedema, M. L., Brizendine, E. J., & Hafner, R. (2001) · Clinical Infectious Diseases · doi:10.1086/323781 · Cited by 96 · see citing works
“albicans obtained from patients in whom fluconazole therapy failed [8].”
Background
Mucosal candidiasis
Vazquez, J. A., & Sobel, J. D. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00042-9 · Cited by 104 · see citing works
Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection?
Goldman, M., Cloud, G. A., Smedema, M. L., LeMonte, A. M., Connolly, P., McKinsey, D. S., Kauffman, C. A., Moskovitz, B. L., & Wheat, L. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1585-1587.2000 · Cited by 88 · see citing works
“development of cross-resistance to itraconazole in fluconazoletreated patients (3).”
Background
Food Interaction and Steady‐State Pharmacokinetics of Itraconazole Oral Solution in Healthy Volunteers
Barone, J. A., Moskovitz, B. L., Guarnieri, J. A., et al. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03856.x · Cited by 89 · see citing works
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
Vazquez, J. (2010) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s6660 · Cited by 81 · see citing works
Treatment of Fluconazole-Refractory Oropharyngeal Candidiasis with Itraconazole Oral Solution in HIV-Positive Patients
Saag, M. S., Fessel, W. J., Kaufman, C. A., Merrill, K. W., Ward, D. J., Moskovitz, B. L., Thomas, C., Oleka, N., Guarnieri, J. A., Lee, J., et al. (1999) · AIDS Research and Human Retroviruses · doi:10.1089/088922299309919 · Cited by 79 · see citing works
“16,17 The present multicenter, open-label study was designed to assess the efficacy and safety of itraconazole oral solution in HIV-positive patients who had fluconazole-refra ctory oropharyngeal candidiasis.”
Efficacy of Caspofungin in the Treatment of Esophageal Candidiasis Resistant to Fluconazole
Kartsonis, N., DiNubile, M. J., Bartizal, K., Hicks, P. S., Ryan, D., & Sable, C. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200210010-00009 · Cited by 77 · see citing works
Photodynamic Therapy of Bacterial and Fungal Biofilm Infections
Biel, M. A. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-697-9_13 · Cited by 77 · see citing works
Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection
Fichtenbaum, C. J., & Powderly, W. G. (1998) · Clinical Infectious Diseases · doi:10.1086/514571 · Cited by 74 · see citing works
“Itraconazole solution has been reported to be effective in several trials in patients with fluconazole-refractory OPC [82-85].”
Background
Therapeutic Options for the Management of Oropharyngeal and Esophageal Candidiasis in HIV/AIDS Patients
Vázquez, J. A. (2000) · HIV Clinical Trials · doi:10.1310/t7a7-1e63-2ka0-jkwd · Cited by 74 · see citing works
A Double‐Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with AIDS
Phillips, P., Beule, K. D., Frechette, G., Tchamouroff, S., Vandercam, B., Weitner, L., Hoepelman, A. I. M., Stingl, G., & Clotet, B. (1998) · Clinical Infectious Diseases · doi:10.1086/516342 · Cited by 71 · see citing works
Self-citation
Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection
Vázquez, J. A., Skiest, D. J., Tissot‐Dupont, H., Lennox, J. L., Boparai, N., & Isaacs, R. (2007) · HIV Clinical Trials · doi:10.1310/hct0802-86 · Cited by 66 · see citing works
Options for the Management of Mucosal Candidiasis in Patients with AIDS and HIV Infection
Vázquez, J. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.1.76.30509 · Cited by 62 · see citing works
AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India
Wadhwa, A., Kaur, R., Agarwal, S. K., et al. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46893-0 · Cited by 62 · see citing works
The management of superficial candidiasis
Hay, R. J. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70396-8 · Cited by 59 · see citing works
ITRACONAZOLE SOLUTION: SUMMARY OF PHARMACOKINETIC FEATURES AND REVIEW OF ACTIVITY IN THE TREATMENT OF FLUCONAZOLE-RESISTANT ORAL CANDIDOSIS IN HIV-INFECTED PERSONS
Koks, C. H. W. (2002) · Pharmacological Research · doi:10.1016/s1043-6618(02)00088-9 · Cited by 50 · see citing works
“A reversible increase in hepatic enzymes was less frequently reported [27, 29, 30].”
Background
Invasive Oesophageal Candidiasis
Vázquez, J. A. (2003) · Drugs · doi:10.2165/00003495-200363100-00004 · Cited by 47 · see citing works
Clinical Experience with Itraconazole in Systemic Fungal Infections
Boogaerts, M., & Maertens, J. A. (2001) · Drugs · doi:10.2165/00003495-200161001-00004 · Cited by 45 · see citing works
A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis
Vázquez, J. A., Schranz, J., Clark, K., Goldstein, B. P., Reboli, A. C., & Fichtenbaum, C. J. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817af47a · Cited by 45 · see citing works
Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts
Metcalf, S. C., & Dockrell, D. H. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.06.012 · Cited by 46 · see citing works
An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis
Lashof, A. M. L. O., Bock, R. D., Herbrecht, R., Pauw, B. E. D., Krcmery, V., Aoun, M., Akova, M., Cohen, J., Šiffnerová, H., Egyed, M., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.003 · Cited by 40 · see citing works
Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection
Fichtenbaum, C. J., Zackin, R. A., Rajicic, N., Powderly, W. G., Wheat, L. J., & Zingman, B. S. (2000) · AIDS · doi:10.1097/00002030-200005050-00011 · Cited by 33 · see citing works
Isavuconazole: A New and Promising Antifungal Triazole for the Treatment of Invasive Fungal Infections
Guinea, J., & Bouza, E. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.603 · Cited by 32 · see citing works
Candidiasis (oropharyngeal).
Pankhurst, C. L. (2012) · PubMed Central · Cited by 37 · see citing works
Oral and Intravenous Itraconazole for Systemic Fungal Infections in Neutropenic Haematological Patients: Meeting Report
Prentice, H. G., Caillot, D., Dupont, B., Menichetti, F., & Schuler, U. S. (1999) · Acta Haematologica · doi:10.1159/000040923 · Cited by 30 · see citing works
“Because the two new formulations have equivalent spectra of activity and bioavailability, only a patient’s inability to take oral medication should delay a switch from intravenous itraconazole to the oral solution.A longer overall period of treatment was considered to be required for aspergillosis than for candidiasis…”
Background
Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list
Dao, A., Kim, H. Y., Halliday, C. L., Oladele, R. O., Rickerts, V., MMed, N. P. G., Shin, J.-H., Heim, J., Ford, N. P., Nahrgang, S. A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae039 · Cited by 29 · see citing works
Prophylaxis and treatment of fungal infections associated with haematological malignancies
Aşçıoğlu, S. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00159-x · Cited by 27 · see citing works
“[78] Phillips P, Zemcov J, Mahmood W, Montaner JS, Craib K, Clarke AM.”
Background
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children
Pienaar, E. D., Young, T., & Holmes, H. K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003940.pub2 · Cited by 25 · see citing works
Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response?
Odds, F. C. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80209-4 · Cited by 19 · see citing works
Oral Candidiasis - A Review. -
Khan, M., Iqubal, M. A., Shukla, A. K., et al. (2014) · International Journal of Health Sciences and Research · Cited by 18 · see citing works
Safety and Efficacy of Single-Dose Fluconazole Compared with a 7-Day Regimen of Itraconazole in the Treatment of AIDS-Related Oropharyngeal Candidiasis
Wit, S. D., O'Doherty, E., Vroey, C. D., et al. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600307 · Cited by 17 · see citing works
Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad
Podzamczer, D., Arribas, J. R., Mallolas, J., Peña, J. M., Pulido, F., Aguirrebengoa, K., Barros, C., Blázquez, R., Costa, J. R., Dronda, F., et al. (2001) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(01)72670-5 · Cited by 17 · see citing works
Fungal Infections in the Immunocompromised Host
Wheat, L. J., Goldman, M., & Sarosi, G. A. (2002) · Springer eBooks · doi:10.1007/0-306-47527-8_6 · Cited by 16 · see citing works
Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 15 · see citing works
“de los pacientes responderá a esta terapia [251, 262].”
Background
Antimicrobial Photodynamic Therapy for Treatment of Biofilm-Based Infections
Biel, M. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-09782-4_8 · Cited by 14 · see citing works
<![CDATA[Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients]]>
Queiroz-Telles, F., Silva, N., Carvalho, M. M., Alc�ntara, A. P., da Matta, D. A., Barberino, M. G., Bartczak, S., & Colombo, A. L. (2001) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702001000200003 · Cited by 14 · see citing works
“isolates [18].”
Oral antifungals as prophylaxis in haematological malignancy
Prentice, A., & Donnelly, P. (2001) · Blood Reviews · doi:10.1054/blre.2001.0145 · Cited by 13 · see citing works
Management of infections caused by Candida glabrata
Sobel, J. D. (2000) · Current Infectious Disease Reports · doi:10.1007/s11908-000-0069-x · Cited by 13 · see citing works
JSMM Clinical Practice Guidelines for Diagnosis and Treatment of Invasive Candidiasis
(2013) · Medical Mycology Journal · doi:10.3314/mmj.54.147 · Cited by 12 · see citing works
The Postantifungal Effect (PAFE) of Itraconazole, in Comparison with Those of Miconazole and Fluconazole, on Candida Species
Uchida, K., Abe, S., & Yamaguchi, H. (2006) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2006.tb03840.x · Cited by 11 · see citing works
Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use
Nett, J. E., & Andes, D. R. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch22 · Cited by 10 · see citing works
Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P
Carrillo‐Muñoz, A. J., Ruesga, M., Brió, S., et al. (2002) · Chemotherapy · doi:10.1159/000066764 · Cited by 8 · see citing works
Susceptibility testing of fungi - current status and open questions
Seibold, M., & Tintelnot, K. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7974-3_5 · Cited by 7 · see citing works
Fungal Opportunistic Infections in HIV Disease
Duffalo, M. L. (2006) · Journal of Pharmacy Practice · doi:10.1177/0897190005284095 · Cited by 6 · see citing works
Candidiasis (oropharyngeal).
Pankhurst, C. L. (2006) · PubMed · Cited by 6 · see citing works
Infecciones fúngicas invasivas en pacientes con hemopatías malignas: una aproximación clínica
García‐Ruiz, J. C., & Pontón, J. (2000) · Medicina Clínica · doi:10.1016/s0025-7753(00)71542-9 · Cited by 6 · see citing works
Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection
Ruhnke, M., Adler, A., & Müller, F. ‐. C. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00041-1.x · Cited by 6 · see citing works
“Itraconazole solution has become an attractive alternative for fluconazole-refractory candidiasis, with temporary clinical response in up to 65% of patients [9,10].”
Background
Management of Oropharyngeal and Esophageal Candidiasis in Patients with Hiv Infection
Vazquez, J. A. (2010) · HIV Therapy · doi:10.2217/hiv.10.18 · Cited by 5 · see citing works
The formation of hyphae of Candida albicans induced by cyclodextrins
Fekete‐Forgács, K., Szabó, E., & Lenkey, B. (1997) · Mycoses · doi:10.1111/j.1439-0507.1997.tb00183.x · Cited by 5 · see citing works
DNA fingerprinting of serialCandida albicansisolates obtained during itraconazole prophylaxis in patients with AIDS
Monte, A. M. L., Goldman, M., Smedema, M. L., et al. (2001) · Medical Mycology · doi:10.1080/mmy.39.2.207.213 · Cited by 4 · see citing works
Candida glabrata: an important fungal pathogen for the 21st century
Fidel, P. L., Vázquez, J. A., & Sobel, J. D. (2001) · Clinical Microbiology Newsletter · doi:10.1016/s0196-4399(01)80058-1 · Cited by 4 · see citing works
Infectious Esophagitis
Namasivayam, V., & Murray, J. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3794-9_46 · Cited by 4 · see citing works
Occurrence of itraconazole-tolerant micromycetes in the soil and food products
Piecková, E., & Jesenská, Z. (1999) · Folia Microbiologica · doi:10.1007/bf02825661 · Cited by 3 · see citing works
Azoles in the Management of Systemic Fungal Infections
Stevens, D. A. (2004) · Infectious Diseases in Clinical Practice · doi:10.1097/01.idc.0000121023.62151.07 · Cited by 2 · see citing works
“Resistance to fluconazole in HIV-infected patients is well documented;(78,79) in these instances, a good option is treatment with itraconazole, which has been shown to be successful in patients who did not respond to fluconazole.(77,80,81)”
Background
Azoles
Andes, D. R., & Dismukes, W. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_5 · Cited by 3 · see citing works
Oral candida species in patients with periodontitis and diabetes mellitus
Hemashree, J., & Geetha, R. V. (2017) · International Journal of Recent Scientific Research · doi:10.24327/ijrsr.2017.0803.0103 · Cited by 1 · see citing works
Oropharyngeal and Esophageal Candidiasis in Immunocompromised Patients: Treatment Issues
Rabih (2016) · Cited by 1 · see citing works
Surveillance of upper aerodigestive candidiasis and their antifungal susceptibility study at tertiary care hospital: A prospective study
Debta, P., Swain, S. K., Dubey, D., Samal, S., Debta, F. M., & Lenka, S. (2024) · Journal of Applied Biology & Biotechnology · doi:10.7324/jabb.2024.146305 · Cited by 1 · see citing works
Gender-Specific Issues in Fungal Infections
KIRMANI, N., & Powderly, W. G. (2004) · Principles of Gender-Specific Medicine · doi:10.1016/b978-012440905-7/50357-1 · Cited by 1 · see citing works
Management of Resistant Candida Infections
Clements, S., & Kibbler, C. C. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-738-3_16 · Cited by 1 · see citing works
Êëèíè÷åñêèå îñîáåííîñòè è òàêòèêà âåäåíèÿ ïàöèåíòîâ ñ êàíäèäîçíûì ïîðàæåíèåì ïîëîñòè ðòà è ãëîòêè
Morozova, O. V. (2011) · CyberLeninK (CyberLeninka)
Systemic fungal infections
Seal, P., & Pappas, P. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-4064-1.00060-9 · Cited by 1 · see citing works
AIDS-Related Mycoses
Bicanic, T. A., Logan, C., Gómez, B. L., Le, T. P., & Wasserman, S. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00057-3
Fungal diseases of the gastrointestinal tract
Schelenz, S. (2017) · doi:10.1093/med/9780198755388.003.0026

Authors: Phillips, P., Zemcov, J., Mahmood, W., Montaner, J. S. G., Craib, K., & Clarke, A. M.
Affiliations: University of British Columbia (CA)
Corresponding author: Phillips, Peter
Mahmood, Wafeeq
Montaner, Julio S.G.
Craib, Kevin
ORCID: Phillips, Peter
Venue: AIDS
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1996-10
Volume: 10
Issue: 12
Pages: 1369-1376
ISSN: 0269-9370 (ISSN-L)
DOI: 10.1097/00002030-199610000-00009
OpenAlex: W2002155710
Cited by: 88
References: 0
Citations by year: 2024: 2 · 2021: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 3
FWCI: 5.54
Type: journal article
Language: en
Open access: closed
Locations: AIDS (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV/AIDS oral health manifestations
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords: oropharyngeal candidiasis, HIV infection, Candida albicans, Candida glabrata, Candida krusei, antifungal susceptibility, clinical response
MeSH terms: Adult, Candidiasis, Oral, Cyclodextrins, Drug Resistance, Microbial, Female, Humans, Male, Middle Aged, Oropharynx, Prospective Studies, Solutions, Fluconazole, AIDS-Related Opportunistic Infections, Itraconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks